Purification of intravenous immunoglobulin G from human plasma – aspects of yield and virus safety

Plasma‐derived intravenous immunoglobulin (IVIG) preparations have been successfully applied for the prophylactic prevention of infectious diseases in immunodeficient patients. In addition to its replacement therapy of primary and secondary antibody deficiencies, IVIG has found increased use in autoimmune and inflammatory diseases. IVIG has become the major plasma product on the global blood product market. The world wide consumption nearly tripled between 1992 and 2003, from 19.4 to 52.6 tons.

[1]  T. Mester,et al.  Prevention of Rh‐Immunization. Modified Production of IgG Anti‐Rh for Intravenous Application by Ion Exchange Chromatography (IEC) 1 , 1973, Vox sanguinis.

[2]  S. Bregenholt,et al.  Pathogen-specific recombinant human polyclonal antibodies: biodefence applications , 2004, Expert opinion on biological therapy.

[3]  R. Rubenstein,et al.  A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins , 2001, Transfusion.

[4]  R. Lemieux,et al.  Therapeutic intravenous immunoglobulins. , 2005, Molecular immunology.

[5]  C. Cunningham.  Production of human immunoglobulin anti-D (Rh0) for intravenous administration, for a national Rh prophylaxis programme [proceedings]. , 1980, Biochemical Society transactions.

[6]  M. Steinbuch,et al.  The isolation of IgG from mammalian sera with the aid of caprylic acid. , 1969, Archives of biochemistry and biophysics.

[7]  P. Hellstern,et al.  In Vitro Characterization of Solvent/Detergent‐Treated Human Plasma and of Quarantine Fresh Frozen Plasma , 1998, Vox sanguinis.

[8]  David P Humphreys.  Production of antibodies and antibody fragments in Escherichia coli and a comparison of their functions, uses and modification. , 2003, Current opinion in drug discovery & development.

[9]  R. Laffin,et al.  A PREPARATIVE METHOD FOR THE SEPARATION OF 7S GAMMA GLOBULIN FROM HUMAN SERUM. , 1964, Archives of biochemistry and biophysics.

[10]  A. Losikoff,et al.  Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration. , 1998, Biologicals : journal of the International Association of Biological Standardization.

[11]  G. Mitra,et al.  Inactivation of hepatitis C virus in low pH intravenous immunoglobulin. , 1994, Biologicals : journal of the International Association of Biological Standardization.

[12]  A Jungbauer,et al.  Continuous Removal of Protein Aggregates by Annular Chromatography , 2001, Biotechnology progress.

[13]  J. Finlayson,et al.  Immunoglobulin G dimer: an idiotype-anti-idiotype complex. , 1988, Molecular immunology.

[14]  H. Saito,et al.  Life‐threatening human parvovirus B19 infection transmitted by intravenous immune globulin , 2002, British journal of haematology.

[15]  H. Suomela.  Inactivation of viruses in blood and plasma products. , 1993, Transfusion medicine reviews.

[16]  M. Korneyeva,et al.  Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates. , 2002, Biologicals : journal of the International Association of Biological Standardization.

[17]  S. Harada,et al.  Elimination of Viruses (Human Immunodeficiency, Hepatitis B, Vesicular Stomatitis and Sindbis Viruses) from an Intravenous Immunoglobulin Preparation , 1987, Vox sanguinis.

[18]  D. Harding,et al.  Hydrophobic charge induction chromatography: salt independent protein adsorption and facile elution with aqueous buffers. , 1998, Journal of chromatography. A.

[19]  P. Ukkonen,et al.  Virus Inactivation during Intravenous Immunoglobulin Production , 1992, Vox sanguinis.

[20]  J. Chermann,et al.  Inactivation and Partition of Human Immunodeficiency Virus during Kistler and Nitschmann Fractionation of Human Blood Plasma 1 , 1988, Vox sanguinis.

[21]  H. Stokes,et al.  Blood protein purification and simultaneous removal of nonenveloped viruses using tangential‐flow preparative electrophoresis , 2005, Electrophoresis.

[22]  J. Curling.  Methods of plasma protein fractionation , 1980 .

[23]  A. Tchorbanov,et al.  The Autoreactivity of Therapeutic Intravenous Immunoglobulin (IVIg) Preparations Depends on the Fractionation Methods Used , 2005, Scandinavian journal of immunology.

[24]  E. Boschetti,et al.  Specific sorbent to remove solvent-detergent mixtures from virus-inactivated biological fluids. , 1995, Journal of chromatography. B, Biomedical applications.

[25]  A. Chanutin,et al.  The precipitation of plasma proteins by short-chain fatty acids. , 1960, Archives of biochemistry and biophysics.

[26]  A. Polson,et al.  Fractionation of Plasma with Polyethylene Glycol , 1972, Vox sanguinis.

[27]  J. Lundblad,et al.  Inactivation of Lipid‐Enveloped Viruses in Proteins by Caprylate , 1991, Vox sanguinis.

[28]  P. Kaplan,et al.  Removal of Hepatitis B Virus Infectivity from Human Gamma‐Globulin Prepared by Ion‐Exchange Chromatography , 1985, Vox sanguinis.

[29]  B. Horowitz,et al.  Virus Inactivation by Solvent/Detergent Treatment and the Manufacture of SD‐Plasma , 1998, Vox sanguinis.

[30]  R. Schiff,et al.  Intravenous gammaglobulin: pharmacology, clinical uses and mechanisms of action , 1994, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[31]  A Jungbauer,et al.  Detection of aggregate formation during production of human immunoglobulin G by means of light scattering. , 2004, Journal of chromatography. A.

[32]  E. Boschetti,et al.  Comparison of hydrophobic charge induction chromatography with affinity chromatography on protein A for harvest and purification of antibodies. , 2001, Journal of chromatography. A.

[33]  A. Farrugia,et al.  Intravenous immunoglobulin: regulatory perspectives on use and supply , 2001, Transfusion medicine.

[34]  Stiehm Er.  Human intravenous immunoglobulin in primary and secondary antibody deficiencies. , 1997 .

[35]  E. Boschetti,et al.  New method for the selective capture of antibodies under physiolgical conditions , 2000, Bioseparation.

[36]  Philip P. Foster,et al.  Removal of TSE agents from blood products , 2004, Vox sanguinis.

[37]  G. Oulundsen,et al.  Incorporation of an additional viral‐clearance step into a human immunoglobulin manufacturing process , 2002, Vox sanguinis.

[38]  M. Sturzenegger,et al.  Adverse Effects of Intravenous Immunoglobulin Therapy , 1999, Drug safety.

[39]  A Jungbauer,et al.  Analysis of aggregates of human immunoglobulin G using size-exclusion chromatography, static and dynamic light scattering. , 2003, Journal of chromatography. A.

[40]  R. D. Francis,et al.  Preparation of human immunoglobulin by caprylic acid precipitation. , 1984, Preparative biochemistry.

[41]  N. Fujii,et al.  Removal of small non‐enveloped viruses by nanofiltration , 2004, Vox sanguinis.

[42]  H. Schuitemaker,et al.  Virus Validation of PH 4-treated Human Immunoglobulin Produced by the Cohn Fractionation Process , 1998 .

[43]  C. Schreiner,et al.  Properties of a new intravenous immunoglobulin (IGIV‐C, 10%) produced by virus inactivation with caprylate and column chromatography , 2003, Vox sanguinis.

[44]  I. Andersson,et al.  Virucidal Treatment of Blood Protein Products with UVC Radiation , 1997, Photochemistry and photobiology.

[45]  A. Denizli,et al.  Pseudo-specific bioaffinity chromatography of immunoglobulin-G , 2004 .

[46]  Y. De Launoit,et al.  Continuous-flow UVC irradiation: a new, effective, protein activity-preserving system for inactivating bacteria and viruses, including erythrovirus B19. , 2004, Journal of virological methods.

[47]  P. Kistler,et al.  Large Scale Production of Human Plasma Fractions , 1962 .

[48]  Deutsch Hf,et al.  Biophysical studies of blood plasma proteins; recovery of gamma-globulin from human blood protein mixtures. , 1946 .

[49]  R. Somerville,et al.  Studies on the removal of a bovine spongiform encephalopathy‐derived agent by processes used in the manufacture of human immunoglobulin , 2002, Vox sanguinis.

[50]  M. Kruskall,et al.  Intravenous immune globulins: an update for clinicians , 2003, Transfusion.

[51]  Humphreys Dp,et al.  Therapeutic antibody production technologies: molecules, applications, expression and purification. , 2001 .

[52]  T. Burnouf,et al.  Nanofiltration of plasma‐derived biopharmaceutical products , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[53]  B. Griffin,et al.  Studies on the Removal of Abnormal Prion Protein by Processes Used in the Manufacture of Human Plasma Products , 2000, Vox sanguinis.

[54]  J. Boose,et al.  Removal of prion challenge from an immune globulin preparation by use of a size‐exclusion filter , 2002, Transfusion.

[55]  P. Højrup,et al.  Characterization of different cell culture media for expression of recombinant antibodies in mammalian cells: Presence of contaminating bovine antibodies. , 2005, Protein expression and purification.

[56]  Y. Uemura.  Dissociation of aggregated IgG and denaturation of monomeric IgG by acid treatment. , 1983, The Tohoku journal of experimental medicine.

[57]  K. Reid,et al.  Inactivation of Viruses during Ultraviolet Light Treatment of Human Intravenous Immunoglobulin and Albumin , 1993, Vox sanguinis.

[58]  Kurt Brorson,et al.  Generic/matrix evaluation of SV40 clearance by anion exchange chromatography in flow‐through mode , 2003, Biotechnology and bioengineering.

[59]  K. Ikuta,et al.  Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparations , 2005, British journal of haematology.

[60]  S. Trejo,et al.  Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process , 2003, Vox sanguinis.

[61]  W. Hughes,et al.  [10] Protein fractionation on the basis of solubility in aqueous solutions of salts and organic solvents , 1955 .

[62]  K. Tanaka,et al.  High quality human immunoglobulin G purified from Cohn fractions by liquid chromatography. , 2000, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[63]  N. Jain,et al.  Risks associated with the use of intravenous immunoglobulin. , 2003, Transfusion medicine reviews.

[64]  F. Malinoski,et al.  Safety profile of WinRho anti-D. , 1998, Seminars in hematology.

[65]  Y. Uemura,et al.  Inactivation and Elimination of Viruses during the Fractionation of an Intravenous Immunoglobulin Preparation: Liquid Heat Treatment and Polyethylene Glycol Fractionation , 1989, Vox sanguinis.

[66]  H. Dichtelmüller,et al.  Inactivation of lipid enveloped viruses by octanoic Acid treatment of immunoglobulin solution. , 2002, Biologicals : journal of the International Association of Biological Standardization.

[67]  R. Stewart,et al.  Purification of human immunoglobulin G: a new approach to plasma fractionation , 2002, Vox sanguinis.

[68]  J. Siegel.  The Product: All Intravenous Immunoglobulins Are Not Equivalent , 2005, Pharmacotherapy.

[69]  J. Sharon,et al.  Construction of polyclonal antibody libraries using phage display. , 2002, Methods in molecular biology.

[70]  D. Mittelman,et al.  A System for the Separation of the Components of Human Blood: Quantitative Procedures for the Separation of the Protein Components of Human Plasma1a,b,c , 1950 .

[71]  A. Vermeer,et al.  Structural changes of IgG induced by heat treatment and by adsorption onto a hydrophobic Teflon surface studied by circular dichroism spectroscopy. , 1998, Biochimica et biophysica acta.

[72]  Kurt Brorson,et al.  Impact of multiple re-use of anion-exchange chromatography media on virus removal. , 2005, Journal of chromatography. A.

[73]  J. Oncley,et al.  The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta1-lipoprotein into subfractions of human plasma. , 1949, Journal of the American Chemical Society.

[74]  C. Lowe,et al.  Affinity chromatography on immobilized "biomimetic" ligands. Synthesis, immobilization and chromatographic assessment of an immunoglobulin G-binding ligand. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[75]  S. Miescher,et al.  Comparative Analysis of Antigen Specificities in the Monomeric and Dimeric Fractions of Intravenous Immunoglobulin , 2005, Annals of the New York Academy of Sciences.

[76]  Alois Jungbauer,et al.  Comparison of protein A affinity sorbents. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[77]  Y. Choi,et al.  Improvement of virus safety of a human intravenous immunoglobulin by low pH incubation , 2001 .

[78]  Y. Uemura,et al.  Inactivation and Elimination of Viruses during Preparation of Human Intravenous Immunoglobulin , 1994, Vox sanguinis.

[79]  C. Kempf,et al.  Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration , 2002, Transfusion.

[80]  J. Bowman,et al.  Column Ion Exchange Chromatographic Production of Human Immune Serum Globulin for Intravenous Use , 1985, Vox sanguinis.

[81]  E J COHN,et al.  Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. , 1946, Journal of the American Chemical Society.

[82]  J. Hotta,et al.  Virus inactivation and protein recovery in a novel ultraviolet‐C reactor , 2004, Vox sanguinis.

[83]  S. Mohri,et al.  Scrapie removal using Planova virus removal filters. , 2001, Biologicals : journal of the International Association of Biological Standardization.

[84]  J. Löwer,et al.  Inactivation of parvovirus B19 during pasteurization of human serum albumin , 2002, Transfusion.